Market Overview

UPDATE: Credit Suisse Upgrades Medtronic to Outperform on Growth Outlook

Share:
Related MDT
Oppenheimer Previews Medtronic's Q4 Earnings, Remains Bullish
Medtronic And Qualcomm To Develop Continuous Glucose Monitoring System
A Historic Race - Investors Focusing On Dividends May Run Out Of Fuel (Seeking Alpha)

Credit Suisse upgraded Medtronic (NYSE: MDT) from Neutral to Outperform and raised the price target from $47.00 to $50.00.

Credit Suisse noted, "MDT's F2H13 & F14 growth aspirations indicate increased confidence that the last 2 quarters of ~5% WW CC growth represent sustainable improvement relative to the flattish top-line growth reported in FY11 & FY12 and further suggest that the growth-oriented acquisitions (Peak, Salient, KH) and increased emerging markets focus that have taken place during CEO Omar Ishrak's early tenure with the company are moving MDT in the right strategic direction."

Medtronic closed at $43.94 on Wednesday.

Latest Ratings for MDT

DateFirmActionFromTo
Apr 2016SunTrust Robinson HumphreyInitiates Coverage onBuy
Mar 2016NomuraInitiates Coverage onBuy
Mar 2016Morgan StanleyMaintainsOverweight

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Upgrades Intraday Update Analyst Ratings

 

Related Articles (MDT)

View Comments and Join the Discussion!